Good evening :)
$
₹
Dermata Therapeutics Inc

Dermata Therapeutics Inc

DRMA

NASDAQ
Asset Logo

Dermata Therapeutics Inc

DRMA

NASDAQ
$1.19—% (+1.19)
$
₹
$1.19—% (+1.19)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Unknown

Sector and industry information not available

Micro Cap

With a market cap of $4.1M the stock is ranked 5986

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

0.08
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.59
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$15.24
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Analysts expect a +726.45% price upside over the next year

Current Price$1.19
Target Price$10

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
70.48
70.48
1Y Return
16.62%
16.62%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
24.45
24.45
1Y Return
34.41%
34.41%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
22.78%
22.78%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.76
30.76
1Y Return
29.71%
29.71%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.97
19.97
1Y Return
37.71%
37.71%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Dermata Therapeutics Inc 0.080.59-
AbbVie Inc70.4850.450.35
Amgen Inc24.4518.181.89

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Frequently asked questions

Frequently asked questions

  1. Dermata Therapeutics Inc (DRMA) share price today is $1.19 as of September 12, 2026 at 1:30 AM IST. The stock touched a day high of $1.25 and a day low of $1.17.

  2. Dermata Therapeutics Inc stock trades on NASDAQ under the ticker symbol DRMA.

  3. Dermata Therapeutics Inc's market capitalization is $4.09M as of September 12, 2026 at 1:30 AM IST.

  4. Dermata Therapeutics Inc's price-to-earnings (P/E) ratio is 0.08 as of September 11, 2026.

  5. Dermata Therapeutics Inc's price-to-book (P/B) ratio is 0.59 as of September 11, 2026.

  6. Yes, You can buy Dermata Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Dermata Therapeutics Inc shares in three steps: 1. Search Dermata Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Dermata Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Dermata Therapeutics Inc (DRMA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 8.3963 shares at the current price of $1.19.

Loading...